首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Ciprofloxacin Treatment Failure in a Murine Model of Pyelonephritis Due to an AAC(6′)-Ib-cr-Producing Escherichia coli Strain Susceptible to Ciprofloxacin In Vitro
【2h】

Ciprofloxacin Treatment Failure in a Murine Model of Pyelonephritis Due to an AAC(6′)-Ib-cr-Producing Escherichia coli Strain Susceptible to Ciprofloxacin In Vitro

机译:鼠环肾炎小鼠模型中环丙沙星治疗失败的原因是体外产生环丙沙星敏感的AAC(6)-Ib-cr产生大肠杆菌菌株

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AAC(6′)-Ib-cr is a plasmid-mediated quinolone resistance mechanism described worldwide for Escherichia coli. Since it confers in vitro only a low level of resistance to ciprofloxacin, we evaluated its impact on the in vivo activity of ciprofloxacin. Isogenic strains were obtained by transferring plasmid p449, harboring aac(6′)-Ib-cr, into the quinolone-susceptible strain E. coli CFT073-RR and its D87G gyrA mutant. MICs were 0.015, 0.06, 0.25, and 0.5 μg/ml against E. coli strains CFT073-RR, CFT073-RR/p449, CFT073-RR GyrAr, and CFT073-RR GyrAr/p449, respectively. Bactericidal activity was reduced at 1× the MIC for the three resistant derivatives, while at a fixed concentration of 0.5 μg/ml, 99.9% killing was observed for all strains except E. coli CFT073-RR GyrAr/p449. In the murine model of pyelonephritis, an optimal regimen of ciprofloxacin (10 mg/kg of body weight twice a day [b.i.d.]) significantly decreased the bacterial count in the kidneys of mice infected with E. coli CFT073 (1.6 versus 4.3 log10 CFU/g of kidney compared to untreated controls; P = 0.0001), while no significant decrease was observed for E. coli CFT073-RR/p449 (2.7 versus 3.1 log10 CFU/g; P = 0.84), E. coli CFT073-RR GyrAr (4.2 versus 4.1 log10 CFU/g; P = 0.35), or E. coli CFT073-RR GyrAr/p449 (2.9 versus 3.6 log10 CFU/g; P = 0.47). While pharmacokinetic and pharmacodynamic (PK/PD) parameters accounted for ciprofloxacin failure against gyrA-containing mutants, this was not the case for the aac(6)-Ib-cr-containing strains, suggesting an in situ hydrolysis of ciprofloxacin in the latter case.
机译:AAC(6')-Ib-cr是世界范围内针对大肠杆菌描述的质粒介导的喹诺酮耐药性机制。由于它在体外对环丙沙星的耐药性较低,因此我们评估了其对环丙沙星体内活性的影响。通过将携带aac(6')-Ib-cr的质粒p449转移到对喹诺酮敏感的菌株E. coli CFT073-RR及其D87G gyrA突变体中,获得同基因菌株。针对大肠杆菌CFT073-RR,CFT073-RR / p449,CFT073-RR GyrA r 和CFT073-RR GyrA r的MIC分别为0.015、0.06、0.25和0.5μg/ ml / p449。三种抗性衍生物的杀菌活性在MIC的1倍处降低,而在固定浓度为0.5μg/ ml时,除大肠杆菌CFT073-RR GyrA r 以外的所有菌株均观察到99.9%的杀灭作用。 / p449。在肾盂肾炎的小鼠模型中,环丙沙星的最佳治疗方案(每天两次,每公斤体重10 mg / kg,[bid])显着降低了感染大肠杆菌CFT073的小鼠肾脏中的细菌数量(1.6对4.3 log10 CFU /与未经治疗的对照组相比,肾脏肾活量为g(P = 0.0001),而大肠杆菌CFT073-RR / p449则未观察到显着降低(2.7对3.1 log10 CFU / g; P = 0.84),大肠杆菌CFT073-RR GyrA < sup> r (4.2 vs 4.1 log10 CFU / g; P = 0.35)或大肠杆菌CFT073-RR GyrA r / p449(2.9 vs 3.6 log10 CFU / g; P = 0.47)。虽然药代动力学和药效学参数(PK / PD)解释了环丙沙星针对含 gyrA 突变体的失败,但 aac(6 ')-并非如此含有Ib-cr 的菌株,表明在后一种情况下环丙沙星的原位水解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号